In 2023, ICON ran its first global biotech survey to understand the sector’s challenges and opportunities. In 2025, we launch the latest edition and for the first time, we conducted a dedicated survey of China- based biotechs. Our global survey captures insights from over 160 biotech leaders worldwide, while the China survey gathers perspectives from 100 executives, in one of the fastest-growing biotech markets. Together, these reports reveal how funding pressures, therapeutic priorities, and co

ICON plc | LinkedIn